Atara Biotherapeutics spent around $58.7 million on operations in the fourth quarter of 2019, for a total cash burn of $235.6 million for the full fiscal year, the company reported Feb. 27. The Thousand Oaks biotech firm raised $36.3 million during the quarter with the sale of some 2.45 million shares of stock, followed by…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
